• Alexandre Chan, Daniel L Hertz, Manuel Morales, Elizabeth J Adams, Sharon Gordon, Chia Jie Tan, Nathan P Staff, Jayesh Kamath, Jeong Oh, Shivani Shinde, Doreen Pon, Niharkia Dixit, James D'Olimpio, Cristina Dumitrescu, Margherita Gobbo, Kord Kober, Samantha Mayo, Linda Pang, Ishwaria Subbiah, Andreas S Beutler, Katherine B Peters, Charles Loprinzi, and Maryam B Lustberg.
• National University of Singapore, Singapore, Singapore.
• Support Care Cancer. 2019 Oct 1; 27 (10): 3729-3737.

AbstractChemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual's specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.

18 keywords...

hide…